Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease. Issue 4 (6th February 2017)

• Record Type: Journal Article
• Authors: Hall, Zoe; Bond, Nicholas J.; Ashmore, Tom; Sanders, Francis; Ament, Zsuzsanna; Wang, Xinzhu; Murray, Andrew J.; Bellafante, Elena; Virtue, Sam; Vidal‐Puig, Antonio; Allison, Michael; Davies, Susan E.; Koulman, Albert; Vacca, Michele; Griffin, Julian L.
• Is Part Of: Hepatology. Volume 65:Issue 4(2017)
• Page Start: 1165
• Page End: 1180
• Publication Date: 2017-02-06
• Subjects: Heart -- Diseases -- Nursing -- Periodicals; Lungs -- Diseases -- Nursing -- Periodicals; Intensive care nursing -- Periodicals; Foie -- Maladies -- Périodiques; 616.362
• DOI: 10.1002/hep.28953
• Languages: English
• ISSNs: 0270-9139

Abstract

Abstract : Nonalcoholic fatty liver disease (NAFLD) can progress from simple steatosis (i.e., nonalcoholic fatty liver [NAFL]) to nonalcoholic steatohepatitis (NASH), cirrhosis, and cancer. Currently, the driver for this progression is not fully understood; in particular, it is not known how NAFLD and its early progression affects the distribution of lipids in the liver, producing lipotoxicity and inflammation. In this study, we used dietary and genetic mouse models of NAFL and NASH and translated the results to humans by correlating the spatial distribution of lipids in liver tissue with disease progression using advanced mass spectrometry imaging technology. We identified several lipids with distinct zonal distributions in control and NAFL samples and observed partial to complete loss of lipid zonation in NASH. In addition, we found increased hepatic expression of genes associated with remodeling the phospholipid membrane, release of arachidonic acid (AA) from the membrane, and production of eicosanoid species that promote inflammation and cell injury. The results of our immunohistochemistry analyses suggest that the zonal location of remodeling enzyme LPCAT2 plays a role in the change in spatial distribution for AA‐containing lipids. This results in a cycle of AA‐enrichment in pericentral hepatocytes, membrane release of AA, and generation of proinflammatory eicosanoids and may account for increased oxidative damage in pericentral regions in NASH. Conclusion : NAFLD is associated not only with lipid enrichment, but also with zonal changes of specific lipids and their associated metabolic pathways. This may play a role in the heterogeneous development of NAFLD. (Hepatology 2017;65:1165‐1180)